Anne Lafond-Walker
Johns Hopkins University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anne Lafond-Walker.
Journal of Clinical Investigation | 1996
Charles J. Lowenstein; Susan L. Hill; Anne Lafond-Walker; Jean Wu; Greg Allen; Mike Landavere; Noel R. Rose; Ahvie Herskowitz
Nitric oxide (NO) is a radical molecule that not only serves as a vasodilator and neurotransmitter but also acts as a cytotoxic effector molecule of the immune system. The inducible enzyme making NO, inducible NO synthase (iNOS), is transcriptionally activated by IFN-gamma and TNF-alpha, cytokines which are produced during viral infection. We show that iNOS is induced in mice infected with the Coxsackie B3 virus. Macrophages expressing iNOS are identified in the hearts and spleens of infected animals with an antibody raised against iNOS. Infected mice have increased titers of virus and a higher mortality when fed NOS inhibitors. Thus, viral infection induces iNOS in vivo, and NO inhibits viral replication. NO is a novel, nonspecific immune defense against viruses in vivo.
Cellular Immunology | 1991
James R. Lane; David A. Neumann; Anne Lafond-Walker; Ahvie Herskowitz; Noel R. Rose
Coxsackie virus B3 (CB3) infection of A/J or A.SW mice results in autoimmune myocarditis characterized by a diffuse mononuclear cell infiltrate and heart-specific autoantibodies. C57BL/10 congenic mice that are identically treated are resistant to this disease. CB3-infected resistant B10.A mice were treated with LPS to determine if this immunomodulator alters disease susceptibility. In contrast to mice infected only with CB3 or treated only with LPS. CB3-infected/LPS-treated (CB3/LPS) B10.A mice developed autoimmune myocarditis similar to that observed in susceptible A/J or A.SW mice. By Day 14, CB3/LPS-induced disease was characterized by significant mortality, myocardial immunoglobulin deposition, and mononuclear cell infiltration of the heart. Immunohistochemical examination revealed deposits of IgG in the heart tissue and serum IgG autoantibodies reactive with sarcolemmal and fibrillary antigens in normal heart tissue. This serum IgG reacted with normal mouse cardiac antigens of a wide range of molecular weights by Western immunoblotting. Because LPS treatment is capable of increasing cytokine levels as well as MHC Class I and Class II expression in heart tissue, it suggests that these factors may contribute to susceptibility to autoimmune myocarditis in CB3-infected mice.
Clinical and Experimental Immunology | 1991
David A. Neumann; James R. Lane; Anne Lafond-Walker; G. S. Allen; S. M. Wulff; Ahvie Herskowitz; Noel R. Rose
This study was undertaken to determine if immunoglobulin G (IgG) antibodies could be eluted from the hearts of mice with Coxsackievirus B3‐induced autoimmune myocarditis and to characterize the immunorcactivity of any elutable autoantibodies. Susceptible (A/J) and resistant (B10.A) mice were administered the virus or the control treatment and killed at various times after treatment. Acid eluates from pooled heart tissue from each treatment group and each time were tested for IgG reactivity with normal heart tissue by immunohistochemistry and with normal heart extracts by Western immunostaining. Eluates from infected A/J mice reacted strongly with syngeneic heart and modestly with syngeneic skeletal muscle tissue. Eluates from infected B10.A or control mice of either strain exhibited little reactivity with either tissue. Tissue reactivity was similar when allogeneic tissue was used as the substrate. Eluates from infected A/J mice recognized the heavy chain of cardiac myosin and several other cardiac antigens by Western immunostaining while eluates from the other treatment groups exhibited little or no reactivity with any normal heart constituents. These results indicate that in vivo IgG deposition occurs in the hearts of mice with post‐infectious autoimmune myocarditis and that the specificity of these antibodies is similar to that reported for serum from animals with this disease. The mechanism(s) leading to myocardial IgG deposition and its possible role in pathogenesis remain to be elucidated.
Experimental Biology and Medicine | 1996
S. K. Bhatia; Noel R. Rose; Brian Schofield; Anne Lafond-Walker; Rudolf C. Kuppers
Abstract Immunization of CBA/J mice with thryoglobulin (Tg) emulsified in complete Freunds adjuvant induces experimental thyroiditis (EAT), a well-characterized model of Hashimotos disease. Recent studies have suggested that dietary factors play a role in the modulation of the immune response and that diet can have a profound effect on the induction of autoimmune diseases. In this study, we examined the influence of diet on autoimmune thyroiditis in mice. EAT was induced in mice fed ad libitum one of the three diets, a standard maintenance chow (Agway H1000), Purina 5020 Breeding Chow, and Purina 5010 Autoclavable (unautoclaved) Diet. Tg-immunized mice fed the Agway 1000 diet were found to be resistant to the development of autoimmune thyroid disease, with only 4 out of 25 mice developing mild thyroiditis. In contrast, 16 out of 25 mice fed the Purina 5010 diet developed moderate to severe thyroiditis. Mice fed the 5020 diet were partly susceptible: 7 out of 25 developed a mild to moderate thyroiditis. Histologic examination of thyroid glands of diseased mice fed the 5010 and 5020 diets showed marked lymphocytic infiltration with destruction of follicles, compared with mice fed the Agway diet, the latter showing only mild infiltration with preservation of thyroid follicles. Titers of antibody to Tg did not differ among the groups, and there was no significant difference in the IgG isotype subclass usage. The results demonstrate that diet can markedly affect the severity of autoimmune disease in the EAT model. In contrast, diet has little effect on the humoral autoimmune response in this system. These results implicate diet as a factor in the severity of cell-mediated autoimmune destruction and suggest that dietary modification could decrease pathology in some forms of autoimmune disease.
Journal of Experimental Medicine | 1998
Kenneth Hung; Robert J. Hayashi; Anne Lafond-Walker; Charles J. Lowenstein; Drew M. Pardoll; Hyam I. Levitsky
Cancer Research | 1998
Robert Z. Orlowski; Anne Lafond-Walker; Michael R. Grever; Marian Orlowski; Chi V. Dang
Journal of Experimental Medicine | 1992
James R. Lane; David A. Neumann; Anne Lafond-Walker; Ahvie Herskowitz; Noel R. Rose
Journal of Immunology | 1993
James R. Lane; David A. Neumann; Anne Lafond-Walker; Ahvie Herskowitz; Noel R. Rose
American Journal of Physiology-heart and Circulatory Physiology | 2002
Haiying Fan; Baogui Sun; Qiuping Gu; Anne Lafond-Walker; Suyi Cao; Lewis C. Becker
Journal of Immunology | 1999
Carlos Zaragoza; Christopher J. Ocampo; Marta Saura; Clare Bao; Michelle K. Leppo; Anne Lafond-Walker; David R. Thiemann; Ralph H. Hruban; Charles J. Lowenstein